Despite the promise of immune checkpoint therapies, treatment-resistant cancers remain a stubborn frontier, making it difficult to predict treatment responsiveness and optimize treatment protocols. A ...
The TIME trial: Phase II randomized controlled trial of time-of-day–specified immunotherapy for advanced melanoma. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract ...
Immatics N.V., a clinical-stage biopharmaceutical company, announced that it will present data on its lead cell therapy candidate, IMA203 TCR T-cell therapy targeting PRAME, at the upcoming 2025 ASCO ...
A new automated process for engineering tumor-targeting T cells could help accelerate personalized cancer treatments—while easing the physical toll on patients. Richard C. Koya, MD, PhD, who directs ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results